Suzanah Boyd

Mrs. Suzanah Boyd


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2017 in Biomarker Research
Verified
Journal Article
Open access
PDF file
GPGulietta M. Pupo
Gulietta M. Pupo
SBSuzanah Boyd
Suzanah Boyd
CFCarina Fung
Carina Fung
MCMatteo S. Carlino
Matteo S. Carlino
AMAlexander M. Menzies
Alexander M. Menzies
Helen RizosHelen Rizos
Helen Rizos
Alternate BRAF splicing is the most common mechanism of acquired resistance to BRAF inhibitor treatment in melanoma. Recently, alternate BRAF exon 4–8 splicing was shown to involve an intronic mutation, located 51 nucleotides upstream of BRAF exon 9 within a predicted splicing branch point. This intronic mutation was identified in a single cell line but has not been examined in vivo. Herein we demonstrate that in three melanomas biopsied from patients with acquired resistance to BRAF inhibitors, alternate BRAF exon 4–8 splicing is not associated with this intronic branch point mutation. We also confirm that melanoma cells expressing BRAF splicing variants retain exquisite sensitivity to existing FDA-approved MEK inhibitors.

23 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
RDRussell Diefenbach
Russell Diefenbach
ASAshleigh Stewart
Ashleigh Stewart
WCWei Yen Chan
Wei Yen Chan
SBSuzanah Boyd
Suzanah Boyd
AMAlexander M. Menzies
Alexander M. Menzies
Helen RizosHelen Rizos
Helen Rizos
Background: Circulating cell-free DNA (cfDNA) enables minimally invasive tumour genomic profiling, yet simultaneous interrogation of mutations and DNA methylation remains limited by assay complexity and input constraints. Methods: Here, we evaluate the Agilent Avida Duo system, a single workflow integrating high-sensitivity mutation detection with targeted DNA methylation analysis. We analysed 21 stage III and IV melanoma patient samples. Results: The Avida Duo mutation assay detected mutant allele frequencies (MAFs) down to 0.05% and identified tumour-associated mutations in all melanoma patients, including within GC-rich regions such as the TERT promoter. Optimisation of the Avida Duo mutation workflow, using TapeStation-quantified cfDNA and reduced amplification cycles, improved library consistency without compromising sensitivity. Methylation profiling of the melanoma baseline cohort with the Avida Duo methylation panel showed high concordance with QIAseq targeted methylation results, with the mean cfDNA fraction methylation ranging from 0.051–0.079 in most patients and reaching 0.249 in the patient with the highest ctDNA burden (MAFs up to 35.4%). Conclusions: Our findings demonstrate that the Avida Duo workflow enables simultaneous, high-resolution detection of mutation and methylation profiles from a single cfDNA sample, streamlining processing and enhancing molecular insight for clinical and translational applications.